newsfilter
← Latest News
GlobeNewswire·

INmune Bio Inc. to Report Second Quarter 2026 Financial Results and Provide Corporate Update on Thursday, August 6th

  • INmune Bio Inc. (NASDAQ: INMB) will host a conference call & webcast on Thursday, August 6, 2026, at 4:30 PM EDT to discuss Q2 2026 results & provide a corporate update.
  • Participants may join by dialing 1-800-717-1738 (US) or +1-646-307-1865 (international) using Conference ID INMUNE, or via the provided webcast link.
  • A transcript will be available approximately 24 hours after the call, with a replay accessible through September 21, 2026, by dialing 1-844-512-2921 or 1-412-317-6671 and entering pin 1166817.
  • The company is advancing CORDStrom™, a mesenchymal stromal cell platform, toward regulatory filing with an MAA planned for the UK MHRA & EU EMA in 2026, alongside a U.S. BLA submission.
  • XPro1595™, a DN-TNF platform with FDA Fast Track designation, is positioned for an integrated Phase 2b/3 adaptive registrational program in early Alzheimer's disease.
  • INmune Bio is a late-stage biotechnology company focused on developing treatments targeting the innate immune system to optimize clinical outcomes through advanced precision medicine.
  • Forward-looking statements in the release are subject to risks & uncertainties, including trial outcomes, funding availability, & regulatory approval timelines.